Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 45 clinical trials
Testing the Addition of the Drugs Apalutamide and Abiraterone Acetate With Prednisone to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer

This phase III trial studies how well adding apalutamide, abiraterone acetate, and prednisone to the usual hormone therapy and radiation therapy works compared to the usual hormone therapy and radiation therapy in treating patients with node-positive prostate cancer after surgery. Radiation therapy uses high energy x-ray to kill tumor cells …

choline
tumor cells
apalutamide
luteinizing hormone-releasing hormone agonist
prostatectomy
  • 72 views
  • 09 Jun, 2021
  • 114 locations
Micronized Progesterone vs Gonadotropin-releasing Hormone (GnRH) Antagonist in Freeze-all IVF Cycles.

To examine whether the number of euploid embryos following ovarian stimulation with micronized progesterone is equivalent as compared with the number of embryos after ovarian stimulation with the use of a GnRH antagonist in patients undergoing ovarian stimulation for IVF or intracytoplasmatic sperm injection (ICSI).

  • 0 views
  • 19 Feb, 2021
  • 1 location
Gonadotropin Releasing Hormone Agonist (GnRHa) Versus Estrogen and Progesterone for Luteal Support in High Responders

Gonadotropin Releasing Hormone agonist (GnRHa) triggering is used as an alternative to human chorionic gonadotropin (hCG) in GnRH antagonist protocol to eliminate the risk of ovarian

  • 0 views
  • 08 Apr, 2021
  • 1 location
Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate Gonadotropin-Releasing Hormone Analog and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery

This randomized phase II trial studies how well androgen receptor antagonist ARN-509 works with or without abiraterone acetate, gonadotropin-releasing hormone agonist, and prednisone in treating

  • 5 views
  • 12 Apr, 2021
  • 1 location
Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Patients Undergoing PGT-A

This randomized trial aims to compare the euploid rate of blastocysts between PPOS and GnRH antagonist protocols in patients undergoing PGT-A. Infertile women who have medical indication for PGT-A will be recruited for study after explanation and counseling if they fulfill the inclusion criteria and do not have the exclusion …

  • 0 views
  • 24 Jan, 2021
  • 1 location
Effect of GnRH Agonist vs GnRH Antagonist on Oocyte Morphology During IVF/ICSI

extracytoplasmic morphologic features. Gonadotropin-releasing hormone agonists (GnRH Agonists) and gonadotropin-releasing hormone antagonists (GnRH Antagonists) are used during controlled ovarian stimulation (COS

  • 0 views
  • 28 Jan, 2021
  • 1 location
Effect of GnRH Agonist vs GnRH Antagonist on Oocyte Morphology in Polycystic Ovary Syndrome Patients During IVF/ICSI

extracytoplasmic morphologic features. Gonadotropin-releasing hormone agonists (GnRH Agonists) and gonadotropin-releasing hormone antagonists (GnRH Antagonists) are used during controlled ovarian stimulation (COS

  • 0 views
  • 03 Feb, 2021
  • 1 location
Skeletal Health and Bone Marrow Composition Among Youth

-releasing hormone (GnRH) agonist medications. This has the possibility of impacting bone development as sex steroids are important to bone mass development. In this multi-site study, the investigators will

  • 0 views
  • 15 May, 2021
  • 1 location
Efficacy and Safety Study of Triptorelin 3-Month Formulation in Chinese Children With Central Precocious Puberty.

overseas CPP population. This is measured by assessing the proportion of children who have a suppressed Luteinizing Hormone (LH) response to Gonadotropin Releasing Hormone (GnRH) test performed 3 months

  • 0 views
  • 14 Apr, 2021
  • 8 locations
Efficacy of FWGE in Combination With Hormone Therapy for the Treatment of Hormone-Refractory Prostate Cancer Patients

line hormone therapy, the gonadotropin releasing hormone (GnRH), which stopped being effective. The study will be conducted during two years with 60 patients. The efficacy will be assessed in

hormone therapy
measurable disease
endocrine therapy
gonadotropin
  • 4 views
  • 07 Nov, 2020
  • 1 location